Prosecution Insights

Browse Companies Examiners Firms Draft Your Response

Last updated: May 29, 2026

Examiner: DRAPER, LESLIE A ROYDS

Tech Center 1600 • Art Units: 1614 1629

This examiner grants 27% of resolved cases

Performance Statistics

27.4%

Allow Rate

-32.6% vs TC avg

818

Total Applications

+43.3%

Interview Lift

1392

Avg Prosecution Days

Based on 785 resolved cases, 2023–2026

Rejection Statute Breakdown

0.3%

§101 Eligibility

75.3%

§102 Novelty

13.5%

§103 Obviousness

2.8%

§112 Clarity

Currently Pending Office Actions

App #	Title	Status	Assignee
19053861	COMPOSITIONS CONTAINING NICOTINAMIDE AND VITAMIN B6 AND METHODS OF USING SUCH COMPOSITIONS FOR REHABILITATION	Non-Final OA	SOCIETE DES PRODUITS NESTLE S.A.
18605928	THERAPEUTIC AGENT FOR OCULAR FUNDUS DISEASE	Non-Final OA	KOWA COMPANY, LTD.
18182511	METHOD OF PREVENTING COCHLEAR DISEASE, DISORDER OR CONDITION USING (+)-AZASETRON	Final Rejection	SENSORION
17911328	METHODS OF TREATING ILLNESSES CAUSED BY CORONAVIRUS, SWINE FLU AND AVIAN FLU	Non-Final OA	CMTx Biotech Inc.
17709710	TOPICAL FORMULATIONS OF 5-ALPHA-REDUCTASE INHIBITORS AND USES THEREOF	Non-Final OA	Varsona Therapeutics, Inc.
17546342	COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE	Final Rejection	LA PharmaTech Inc.
17430168	METHODS FOR INCREASING GROWTH IN PEDIATRIC SUBJECTS HAVING CHOLESTATIC LIVER DISEASE	Non-Final OA	MIRUM PHARMACEUTICALS, INC.
17274726	Use of CFTR Modulators For Treating Cerebrovascular Conditions	Final Rejection	Qanatpharma AG

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy